p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
about
Prognostic significance of copy-number alterations in multiple myelomaNovel strategies to target the ubiquitin proteasome system in multiple myelomaSellar solitary plasmacytoma progressing to multiple myeloma: a case report and literature reviewDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaGallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cellsTargeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myelomaChromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.p53 abnormalities and potential therapeutic targeting in multiple myeloma.Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.The DAC system and associations with multiple myeloma.Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.Targeting p53 by small molecules in hematological malignancies.Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsImpact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.Prediction of cytogenetic abnormalities with gene expression profiles.PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.Genetic events in the pathogenesis of multiple myeloma.Microarray-based understanding of normal and malignant plasma cells.Clinical implications of chromosomal abnormalities in multiple myeloma.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Review of molecular diagnostics in multiple myeloma.An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaGenomics in multiple myeloma.Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesClinical impact of chromosomal aberrations in multiple myeloma.Plasma cell myeloma and related neoplasms.Genomic stratification of multiple myeloma treated with novel agents.Understanding the molecular biology of myeloma and its therapeutic implications.Staging and prognostication of multiple myeloma
P2860
Q24643402-5086DF92-92A5-4441-B744-C85007075168Q26773246-729EAF21-27ED-4CD8-B4E2-BF0166705089Q26829219-47F32431-5E1E-44D1-9DAD-1AEA913297C1Q27692033-C9804589-2F6F-4A07-826C-CB48D49D494AQ28074490-194E3F49-B7A0-461E-AD03-26FF83C94CACQ28387391-E88366AD-58C1-4A82-B2C8-B72B35E1ECDDQ28479002-B6170831-6E04-4A97-AAEE-431DAF04A3CDQ31154933-CC33255A-FC7E-400A-8898-E2ADAF4C1EADQ33394977-A0F789DF-49D3-4172-9A1D-22D08DEABFF7Q33721123-1CBB8809-EB5B-49ED-9903-597EEF102D03Q33846310-78E65C26-D431-4B7C-8BFD-6CF558ED54F6Q33852683-23B453A3-66BC-4698-938A-B80EDBB17657Q33952805-900BF04F-C783-4C88-A986-28F4DFA797A0Q34241661-83179D41-4934-4920-B863-1CD28EDD5003Q34296442-945AAC4D-F981-4CF3-8AD5-25A3A5D914BEQ34414447-71D94CF1-0F68-4114-A3D9-5DCB7960E437Q34448995-1036059A-25C5-4D24-AC34-29BCDA637F6CQ34636996-11906004-EB41-4C15-904C-FE8311BCFF88Q34769841-F105114B-E260-439A-9E80-DECF58F0560CQ34993904-94F48768-727B-43A4-865A-AB92F10A9BBBQ35081172-8707BF4E-2ED8-4130-A47F-945644469AC8Q35265979-F1DA33AA-CAE3-46F2-B609-FB96CE524CD3Q35849219-D8881F3E-0B67-445E-9361-478EB65EA923Q35984702-22593947-1897-4859-8718-28A0BE8F5265Q36010314-FAE0CEFB-903D-4518-BC38-C8C6739C1D7EQ36126937-1D3943E0-E016-4714-BAC6-533619D84D2DQ36380235-489492ED-CDBD-4D1C-A282-2531E8B73C5CQ36453354-2A88D8C6-D523-4248-BFB2-F1E3C70E4456Q36497416-D2EB631B-D7B4-4C57-8DDA-40F09F0306B9Q36595290-9ECE9EF9-331E-4C37-9386-814706F02E4CQ36874362-07AD66C5-3929-4124-A83E-0735DD611247Q36969724-4E45EBD4-F1CE-4505-A000-18340C4E8E8EQ37197359-121398DA-E35D-4176-A708-3F5A825597F5Q37367737-A2B22CD5-21A2-4A85-BD4F-0785353E5B26Q37454445-793A71EF-DA73-4527-B681-289D129455C6Q37821077-4A3A069E-0D29-4300-BCCA-B2DC37CE5252Q37901231-0D101A1F-1FC1-4B7B-A201-BC2A10E0E867Q37913346-B14CBC0A-33CB-4C5E-B2B4-5FC6F402DBB6Q38065305-094A853B-465C-4812-BCC0-AB107F22D844Q38183871-F24CC699-6D9B-4826-9825-A6513F7D1402
P2860
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
p53 gene deletion detected by ...... ous stem cell transplantation.
@en
p53 gene deletion detected by ...... ous stem cell transplantation.
@nl
type
label
p53 gene deletion detected by ...... ous stem cell transplantation.
@en
p53 gene deletion detected by ...... ous stem cell transplantation.
@nl
prefLabel
p53 gene deletion detected by ...... ous stem cell transplantation.
@en
p53 gene deletion detected by ...... ous stem cell transplantation.
@nl
P2093
P1433
P1476
p53 gene deletion detected by ...... ous stem cell transplantation.
@en
P2093
A Keith Stewart
Donna Reece
Hong Chang
Qi-Long Yi
P304
P356
10.1182/BLOOD-2004-04-1363
P407
P577
2004-08-31T00:00:00Z